Scientists Find Safer Way to Make Common Blood Thinner Heparin
Using human cells instead of pig intestine likely to reduce the risk of deadly contamination; new method could fuel shift in the multibillion dollar global heparin market
Article ID: 650449
Released: 30-Mar-2016 8:00 AM EDT
Source Newsroom: Federation of American Societies for Experimental Biology (FASEB)
Newswise — San Diego (April 5, 2016) – For the first time, scientists have discovered a way to make the common blood-thinning medication heparin using human cells in the laboratory. The new method could offer a safer alternative to current heparin production methods, which rely on animal byproducts such as pig intestine that are largely sourced in China.
Hundreds of U.S. patients have experienced adverse reactions and at least 81 have died as a result of contamination found in Chinese-sourced heparin in recent years, prompting the U.S. Food and Drug Administration to issue import alerts and large-scale recalls.
“When we started this study, we were very surprised that in this century people would still be using an animal extract to produce a drug,” said John Whitelock, Ph.D., head of the Graduate School of Biomedical Engineering at the University of New South Wales, who led the research team. “What we’ve done is looked at the way our cells naturally make heparin in our bodies, taken that gene, and expressed it in cells in the laboratory. The result is a natural product that is not synthetic, which makes it safer than the animal-sourced material.”
Whitelock will present the research at the American Society for Biochemistry and Molecular Biology Annual Meeting during Experimental Biology 2016.
Heparin is a blood-thinning drug commonly used to prevent blood clots in patients undergoing surgery or dialysis. An estimated 12 million patients receive heparin each year in the United States alone. The drug, discovered in 1916 and one of the oldest still in widespread use, is on the World Health Organization’s List of Essential Medicines and represents a multibillion dollar global market.
The vast majority of heparin used today comes from a complex supply chain based in China, where a crude form of the drug is manufactured using extracts from pig intestine or cattle lung tissue. Contamination events have been traced to inappropriate handling of animal tissues and to intentional adulteration.
The method developed by Whitelock and colleagues eliminates the use of animal tissues altogether. Taking advantage of our bodies’ natural ability to produce heparin, the researchers induced laboratory-grown human kidney cells to increase the expression of the serglycin gene, thought to be responsible for heparin production. They then tested the blood-thinning properties of the resulting substance.
“Frankly, we were surprised that there was any anticoagulant effect at all,” said Whitelock. “People in this field have been working with serglycin for upwards of 20 years, and usually you get a sort of heparin ‘cousin’ but not real heparin. It’s been a great source of frustration, and our study is an important step toward an alternative source of heparin that could have distinct advantages for patient safety.”
The difficulty of producing heparin from human cells stems from the fact that heparin is a carbohydrate, a structurally complex sugar, whereas most drugs produced from cells are proteins, which are quite different in terms of structure. This study represents the first time researchers have been successful in inducing human cells to produce a carbohydrate-only drug.
The study also sheds light on a mystery that has stymied heparin researchers for much of the drug’s history. Generations of chemists have attempted to create heparin without the use of animal tissues by mimicking the carbohydrate’s precise chemical structure; however, animal-derived heparin has remained more effective than these artificial forms. Whitelock’s study shows that heparin produced by human cells has a natural variability—small tweaks in carbohydrate structure that give a more diverse biological mix than what would be produced in a chemistry lab.
“Heparin is a very important drug that’s been misunderstood for the last 100 years,” said Whitelock. “People thought it needed a particular structure to have its effect, but our study shows that we might actually need a bit of natural variation to get a really good clinical outcome.”
The team’s next steps are to refine the engineered cells to increase the amount and potency of the heparin they produce. Whitelock estimates heparin produced with the new method could hit the market within 10-15 years, although he cautioned that the drug will likely be more expensive than traditional animal-derived heparin because of the economies of scale that are already built into the existing supply chain. However, human cell-derived heparin could potentially be significantly safer, less prone to contamination and adverse reactions, and a better option for patients who currently cannot use animal-derived heparin due to religious or dietary restrictions.
Whitelock will present these findings during the Experimental Biology 2016 meeting on Tuesday, April 5 from 12:00 to 1:30 PM at the Recent Advances in Protein Engineering session in Exhibit Halls A-D (poster number C114), San Diego Convention Center. Colleague Megan Lord will present related research on Sunday, April 3 from 12:30 to 2:00 PM at the Glycobiology and Extracellular Matrix session in Exhibit Halls A-D (poster number C241) and in an oral presentation on Tuesday, April 5 at 10.55 AM in Room 1A, San Diego Convention Center. The study was funded by the University of New South Wales and grants from the Australian Research Council, Australian Government.
About Experimental Biology 2016 Experimental Biology is an annual meeting comprised of more than 14,000 scientists and exhibitors from six sponsoring societies and multiple guest societies. With a mission to share the newest scientific concepts and research findings shaping clinical advances, the meeting offers an unparalleled opportunity for exchange among scientists from across the United States and the world who represent dozens of scientific areas, from laboratory to translational to clinical research. www.experimentalbiology.org
About the American Society for Biochemistry and Molecular Biology (ASBMB) ASBMB is a nonprofit scientific and educational organization with more than 12,000 members worldwide. Founded in 1906 to advance the science of biochemistry and molecular biology, the society publishes three peer-reviewed journals, advocates for funding of basic research and education, supports science education at all levels, and promotes the diversity of individuals entering the scientific workforce. www.asbmb.org
MEDIA CONTACT Nancy Lamontagne (919) 617-1330 email@example.com
ONSITE NEWSROOM San Diego Convention Center April 2-6, 2016 (619) 525-6239